Epigenomics: Greg Hamilton

Epigenomics announced the resignation of Greg Hamilton as CEO and as a member of the firm's executive board, effective June 30. He has been the company's CEO since July 2016. The German cancer diagnostics firm said the changes are in connection with its recent revised strategy. In February, Epigenomics announced a restructuring, including the recall of its Epi proColon test for colorectal cancer, staff cuts, and a reduction of its remaining operations. The company also said it will have discussions with its executive board about the future composition of the executive board.